Tang Jian, Yao Deyi, Yan Haiying, Chen Xing, Wang Linjia, Zhan Huakui
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan, China.
Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan, China.
Int J Endocrinol. 2019 Dec 1;2019:8719060. doi: 10.1155/2019/8719060. eCollection 2019.
Diabetic nephropathy (DN) is one of the most common microvascular complications in diabetic patients; it is also an important cause of renal dysfunction, renal fibrosis, and end-stage renal disease. Unfortunately, the pathogenesis of DN is complex and has not yet been fully elucidated; hence, the pathogenesis of DN to determine effective treatments of crucial importance is deeply explored. Early DN research focuses on hemodynamic changes and metabolic disorders, and recent studies have shown the regulatory role of microRNAs (miRNAs) in genes, which may be a new diagnostic marker and therapeutic target for diabetic nephropathy. In this review, we summarize the recent advances in the clinical value and molecular mechanisms of miRNAs in DN, providing new ideas for the diagnosis and treatment of DN.
糖尿病肾病(DN)是糖尿病患者最常见的微血管并发症之一;它也是肾功能不全、肾纤维化和终末期肾病的重要原因。不幸的是,DN的发病机制复杂,尚未完全阐明;因此,深入探究DN的发病机制对于确定有效的治疗方法至关重要。早期DN研究集中在血流动力学变化和代谢紊乱方面,最近的研究表明微小RNA(miRNA)在基因中具有调控作用,这可能是糖尿病肾病的一种新的诊断标志物和治疗靶点。在本综述中,我们总结了miRNA在DN中的临床价值和分子机制的最新进展,为DN的诊断和治疗提供新思路。